KRYS
HealthcareKrystal Biotech, Inc. · Biotechnology · $9B
What is Krystal Biotech, Inc.?
Krystal Biotech is a Pittsburgh-based biotechnology company focused on redosable gene therapy for serious rare diseases. Its pipeline targets debilitating skin and respiratory conditions with a platform designed for repeated administration.
Krystal Biotech develops gene therapies that can be redosed — a meaningful distinction from traditional one-time gene therapy approaches. Its lead program targets dystrophic epidermolysis bullosa, a severe rare skin disease. Beyond that lead asset, the company is advancing candidates for congenital ichthyosis, cystic fibrosis, Netherton syndrome, and aesthetic skin conditions. Revenue potential is tied to clinical success and eventual commercialization of these programs.
Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech has built its pipeline around a proprietary gene therapy delivery approach.
- Beremagene geperpavec (B-VEC) — lead gene therapy for dystrophic epidermolysis bullosa
- KB105 — Phase I/II candidate for autosomal recessive congenital ichthyosis
- KB301 — Phase I/II candidate for aged or damaged skin conditions
- KB407 — preclinical program targeting cystic fibrosis
- KB104 — preclinical program for Netherton syndrome
Is KRYS a Good Stock to Buy?
UQS Score rates KRYS as Good overall, reflecting a balanced profile across its five analytical pillars.
The Growth and Risk pillars both register as Strong — an uncommon combination for a clinical-stage biotech. Growth reflects the pipeline's commercial momentum and rare-disease focus, while the Risk profile suggests the company carries relatively contained financial and operational risk compared to many development-stage peers.
The Moat pillar reads as Neutral, indicating that durable competitive advantages are still being established as the platform matures. Valuation is also Neutral, suggesting the market has already priced in a meaningful portion of the pipeline's potential.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does KRYS pay dividends?
No — Krystal Biotech, Inc. does not currently pay a dividend.
Krystal Biotech does not currently pay a dividend. For a clinical-stage biotech, this is standard practice — capital is directed toward advancing the pipeline through clinical trials and toward potential commercialization. Investors in KRYS are generally seeking growth from pipeline milestones rather than income from distributions.
When does KRYS report earnings?
Krystal Biotech reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a company transitioning from pure development toward early commercialization, quarterly results reflect both pipeline progress and evolving revenue dynamics. Investors typically watch for updates on B-VEC uptake and clinical readouts alongside financial results.
For the most recent quarter's results and upcoming reporting dates, visit Krystal Biotech's investor relations page directly.
KRYS Price History
+317.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Krystal Biotech, Inc.?
Based on Krystal Biotech, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
KRYS Long-term Outlook
The Strong Growth pillar signals that Krystal Biotech's pipeline is at a stage where meaningful commercial progress is anticipated. The rare-disease focus — particularly in dermatology — offers a relatively defined patient population and potential for orphan drug pricing dynamics. The Strong Risk profile adds confidence that the company is not overleveraged heading into this phase. However, the Neutral Valuation pillar suggests limited margin of safety at current levels, making execution on near-term milestones especially important.
Growth drivers
- Commercial ramp of B-VEC in dystrophic epidermolysis bullosa
- Pipeline advancement across multiple rare skin and respiratory disease programs
- Redosable gene therapy platform differentiation in a competitive rare-disease landscape
Key risks
- Clinical trial outcomes remain binary and unpredictable for pipeline assets
- Neutral Valuation pillar limits upside if commercial execution disappoints
- Rare-disease market size caps revenue ceiling relative to larger therapeutic areas
KRYS vs Peers
Krystal Biotech operates in a competitive rare-disease and specialty biotech space alongside companies with distinct platform strategies.
Halozyme focuses on drug delivery technology licensed to large pharma partners rather than building its own rare-disease pipeline.
Cytokinetics targets cardiovascular muscle biology, competing for rare-disease investor attention with a different therapeutic focus.
ImmunityBio pursues cancer immunotherapy, representing a broader oncology approach compared to Krystal's dermatology-centered gene therapy platform.
Frequently Asked Questions
What does Krystal Biotech do?
Krystal Biotech develops redosable gene therapies for serious rare diseases, with a primary focus on severe skin conditions. Its lead product targets dystrophic epidermolysis bullosa, and its broader pipeline spans additional rare skin diseases and cystic fibrosis. The redosable nature of its platform sets it apart from conventional one-time gene therapy approaches.
Does KRYS pay dividends?
KRYS does not pay a dividend. As a clinical-stage biotech company, Krystal Biotech reinvests available capital into pipeline development and commercialization efforts. Investors in KRYS are typically focused on pipeline-driven growth rather than income.
When does KRYS report earnings?
Krystal Biotech reports on a quarterly cadence, as is standard for US-listed companies. For the most current earnings schedule and recent results, check the investor relations section of Krystal Biotech's official website.
Is KRYS a good stock to buy?
UQS Score rates KRYS as Good overall. The Growth and Risk pillars are both Strong, which is notable for a clinical-stage biotech. The Moat and Valuation pillars are Neutral, suggesting the stock is fairly priced with competitive advantages still developing. The complete pillar breakdown is available to Pro members.
Is KRYS overvalued?
The UQS Valuation pillar for KRYS reads as Neutral, indicating the market has priced in a reasonable portion of the pipeline's potential without appearing deeply discounted or significantly stretched. Investors should weigh this against the Strong Growth profile when forming their own view.
How does KRYS compare to its competitors?
Krystal Biotech's redosable gene therapy platform is a differentiating feature relative to peers like Halozyme, Cytokinetics, and ImmunityBio, each of which pursues distinct therapeutic strategies. KRYS's rare-disease dermatology focus gives it a narrower but potentially high-value commercial target. Full UQS comparisons across pillars are available to Pro members.
What is KRYS's market cap bracket?
KRYS is classified as a mid-cap stock. This places it in a range where the company has moved beyond early-stage obscurity but still carries meaningful growth potential relative to large- or mega-cap peers in the healthcare sector.
Who founded Krystal Biotech?
Krystal Biotech was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Founding details are widely available through the company's public filings and investor relations materials.
Is KRYS a long-term quality stock?
From a quality indicator perspective, KRYS earns a Good overall UQS Score with particularly Strong marks on Growth and Risk. Long-term quality depends on continued pipeline execution and whether the Moat pillar strengthens as the platform matures commercially. Pro members can view the full pillar breakdown to assess long-term positioning.
What is the main competitive advantage of Krystal Biotech?
Krystal Biotech's core differentiator is its redosable gene therapy platform, which allows treatments to be administered multiple times — unlike traditional gene therapies. This approach may offer advantages in chronic or progressive diseases where a single treatment is insufficient. The UQS Moat pillar currently rates this advantage as Neutral as the platform continues to prove itself commercially.
What sector does KRYS belong to?
KRYS operates in the Healthcare sector, specifically within biotechnology. Its focus on rare genetic skin diseases and gene therapy places it in a specialized niche within the broader biotech landscape. Investors can explore other [top healthcare stocks](/sector/healthcare) rated by UQS Score.
Is KRYS a growth stock or value stock?
Based on its UQS pillar profile, KRYS leans toward the growth category — the Growth pillar is rated Strong, reflecting active pipeline advancement and commercial potential. The Valuation pillar is Neutral, meaning it does not screen as a deep-value opportunity. It fits the profile of a growth-oriented biotech at a fair market price.
Unlock Full KRYS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare KRYS to peers across every quality dimension
- ✓See Growth and Risk pillar detail behind the score
- ✓Get the complete analyst-grade breakdown in one view
Pro Analysis
KRYS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 63.7 | 72.2 | 46.0 | 80.0 | 82.4 | 38.8 | +0.1 |
| May 16, 2026 | 63.6 | 72.1 | 46.0 | 80.0 | 82.4 | 38.2 | +0.2 |
| May 15, 2026 | 63.4 | 72.0 | 46.0 | 80.0 | 82.4 | 36.9 | -0.1 |
| May 14, 2026 | 63.5 | 72.0 | 46.0 | 80.0 | 82.4 | 37.4 | -0.1 |
| May 11, 2026 | 63.6 | 72.1 | 46.0 | 80.0 | 82.4 | 38.3 | +0.3 |
| May 7, 2026 | 63.3 | 70.7 | 46.0 | 80.0 | 82.4 | 38.8 | -0.5 |
| May 6, 2026 | 63.8 | 70.7 | 46.0 | 80.0 | 82.4 | 42.1 | -0.1 |
| May 3, 2026 | 63.9 | 70.7 | 46.0 | 80.0 | 82.4 | 42.6 | +0.1 |
| Apr 29, 2026 | 63.8 | 70.7 | 46.0 | 80.0 | 82.4 | 41.6 | -0.1 |
| Apr 26, 2026 | 63.9 | 70.7 | 46.0 | 80.0 | 82.4 | 42.7 | 0.0 |
KRYS — Pillar Breakdown
Quality
— 72.3/100 (25%)Krystal Biotech, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)Krystal Biotech, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Krystal Biotech, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 39.1/100 (15%)Krystal Biotech, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Krystal Biotech, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KRYS.
Score Composition
Financial Data
More Stock Analysis
How is the KRYS UQS Score Calculated?
The UQS (Unified Quality Score) for Krystal Biotech, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Krystal Biotech, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Krystal Biotech, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.